Pandorum Technologies occupies a distinctive position as India's first bioprinting company to create lab-grown human tissues, addressing gaps in drug testing accuracy and corneal blindness treatment. Founded in 2011, the company differentiates itself from global peers like Organovo and CELLINK by focusing on the Indian market and developing a cure for corneal blindness through its Kuragenx Liquid Cornea therapy.
The company's core technology is a proprietary bioprinting platform designed for high-precision tissue engineering. Its key products include engineered liver and corneal models for pharmaceutical drug testing, alongside the Kuragenx therapy for regenerative medicine. These models aim to reduce reliance on animal testing and improve preclinical prediction of human drug responses.
Pandorum targets pharmaceutical companies, research institutions, and hospitals, with multiple pharmaceutical partnerships in place. The company achieved a notable milestone in 2016 by creating India's first 3D printed human liver tissue. As of FY24, it remains pre-revenue but carries a valuation of ₹401 crore, supported by investors including Protons Corporate, Ashish Kacholia, and the Indian Angel Network.
The company's strategic moat lies in its first-mover advantage in India's bioprinting sector and its focus on corneal blindness, a large unmet need. However, it faces competitive risk from established global bioprinting firms and must demonstrate commercial traction to justify its valuation. The recent INR 85 crore Series B led by Protons Corporate signals continued investor confidence in its path to revenue.
Watch Pandorum Technologies
Save it to your watch list and return here after authentication.